AU2020366147B2 - Transdermal delivery of cannabidiol - Google Patents

Transdermal delivery of cannabidiol Download PDF

Info

Publication number
AU2020366147B2
AU2020366147B2 AU2020366147A AU2020366147A AU2020366147B2 AU 2020366147 B2 AU2020366147 B2 AU 2020366147B2 AU 2020366147 A AU2020366147 A AU 2020366147A AU 2020366147 A AU2020366147 A AU 2020366147A AU 2020366147 B2 AU2020366147 B2 AU 2020366147B2
Authority
AU
Australia
Prior art keywords
pain
days
transdermal
once
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020366147A
Other languages
English (en)
Other versions
AU2020366147A1 (en
Inventor
Marina BOROVINSKAYA
Tamanna LATHER
Nisarg MODI
Fotios M. Plakogiannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of AU2020366147A1 publication Critical patent/AU2020366147A1/en
Assigned to Pike Therapeutics Inc. reassignment Pike Therapeutics Inc. Amend patent request/document other than specification (104) Assignors: Pike Therapeutics Inc., 1219014 B.C. Ltd.
Application granted granted Critical
Publication of AU2020366147B2 publication Critical patent/AU2020366147B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020366147A 2019-10-14 2020-10-13 Transdermal delivery of cannabidiol Active AU2020366147B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914662P 2019-10-14 2019-10-14
US62/914,662 2019-10-14
PCT/IB2020/059608 WO2021074790A1 (en) 2019-10-14 2020-10-13 Transdermal delivery of cannabidiol

Publications (2)

Publication Number Publication Date
AU2020366147A1 AU2020366147A1 (en) 2022-04-07
AU2020366147B2 true AU2020366147B2 (en) 2024-09-05

Family

ID=75382383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020366147A Active AU2020366147B2 (en) 2019-10-14 2020-10-13 Transdermal delivery of cannabidiol

Country Status (8)

Country Link
US (1) US12097293B2 (enExample)
EP (1) EP4045024A4 (enExample)
JP (1) JP2022551730A (enExample)
CN (1) CN114555068A (enExample)
AU (1) AU2020366147B2 (enExample)
CA (1) CA3155181A1 (enExample)
MX (1) MX2022004258A (enExample)
WO (1) WO2021074790A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2023006561A (es) * 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
WO2022215030A1 (en) * 2021-04-08 2022-10-13 Pike Therapeutics Inc., 1219014 B.C. Ltd Pharmaceutical composition and method for treating seizure disorders
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
AU2022260813A1 (en) * 2021-04-22 2023-10-26 Pike Therapeutics Inc. Transdermal pharmaceutical formulations for the treatment of chronic pain
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
WO2024069613A1 (en) * 2022-09-30 2024-04-04 Atomix Pharmaceuticals Inc. Compositions and methods for the treatment of temporomandibular joint disorder
CN117224476A (zh) * 2023-08-30 2023-12-15 黑龙江钲拓农业发展有限公司 一种具有抗过敏作用的大麻二酚药用搽剂及其制备方法
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273895A1 (en) * 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
WO2019140321A1 (en) * 2018-01-12 2019-07-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
EP1109533A1 (en) 1999-07-08 2001-06-27 Orlando Hung Pulmonary delivery of liposome-encapsulated cannabinoids
US20050042271A1 (en) 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
WO2001064149A1 (en) 2000-02-29 2001-09-07 Jie Zhang Improved transdermal drug patch
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US20180042842A1 (en) 2001-02-14 2018-02-15 Gw Pharma Limited Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
EP1542657B8 (en) 2002-08-14 2012-03-14 GW Pharma Limited Cannabinoid liquid formulations for mucosal amdinistration
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
EP1559423A1 (en) 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7671052B2 (en) 2004-10-05 2010-03-02 Adolor Corporation Phenyl derivatives and methods of use
WO2006044645A2 (en) 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US7544676B2 (en) 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US8481085B2 (en) 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2008006226A1 (en) 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
EP2083825A4 (en) 2006-09-26 2009-11-04 Addiction Res Inst Inc HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS
WO2008063625A2 (en) 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
WO2009020666A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
JP5620907B2 (ja) 2008-06-19 2014-11-05 エルテーエスローマン テラピー−ジステーメ アーゲー カチオン性活性剤の経皮送達のための組成物
EP2363116A1 (en) 2008-06-25 2011-09-07 US Worldmeds LLC Sustained-release formulations comprising lofexidine for oral delivery
EP2424568A1 (en) 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
US20130253449A1 (en) 2010-12-07 2013-09-26 Yutoku Pharmaceutical Industries Co., Ltd. Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
US8642645B2 (en) 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US20130022687A1 (en) 2011-07-19 2013-01-24 Fitzgerald Jr John James Topical transdermal method for delivering nutrients through the skin for expedited wound healing
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
US9763912B2 (en) 2013-10-30 2017-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
US10064905B1 (en) 2013-11-11 2018-09-04 Ilysm, LLC Pharmaceutical preparation
US10555927B2 (en) 2013-11-11 2020-02-11 Ilysm, LLC Compositions and methods for enhancing sexual pleasure and performance
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
WO2015140736A1 (en) 2014-03-18 2015-09-24 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
US10118006B2 (en) 2014-06-30 2018-11-06 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2016004121A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
US20160039591A1 (en) 2014-07-22 2016-02-11 Craig E. Kinzer Packaging systems, devices, methods, and composition including cannabinoid unit dose forms
AU2015308546A1 (en) 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
CA2859930A1 (en) 2014-09-22 2016-03-22 Antony Paul Hornby A cannabis topical from heat treated cocount oil
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
CA2966710A1 (en) 2014-11-03 2016-05-12 Ramot At Tel Aviv University Ltd. Methods for treatment of cognitive decline
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016092539A1 (en) 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
WO2016103254A1 (en) 2014-12-21 2016-06-30 One World Cannabis Ltd Use of cannabis to treat psoriasis
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
EP3253368A4 (en) 2015-02-02 2018-08-22 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
BR112017018944A2 (en) 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
EP3268086A4 (en) 2015-03-10 2018-11-07 Eleusis Benefit Corporation, PBC Lsd for the treatment of alzheimer's disease
EP3270896A4 (en) 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
MX2018000844A (es) 2015-07-22 2018-07-06 Phytopharma Int Ltd Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera.
US9827282B2 (en) 2015-07-24 2017-11-28 Bao Tran Medication dispensing system
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2995418A1 (en) 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
MX2018004034A (es) 2015-09-30 2018-12-19 Edward Hoag George Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos.
US10695287B2 (en) 2015-11-17 2020-06-30 Cersci Therapeutics, Inc. AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same
US20170202895A1 (en) 2016-01-18 2017-07-20 Kevin Anthony Hugh Cannabis Pellets
US10338355B2 (en) 2016-02-05 2019-07-02 Largan Precision Co., Ltd. Lens assembly
PT3429580T (pt) 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN109069459A (zh) 2016-04-12 2018-12-21 哈比制药私人有限公司 脂质体制剂和治疗方法
LT6486B (lt) 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
WO2017182950A1 (en) 2016-04-19 2017-10-26 Canabuzz-Med Cannabis-enriched enzymatically treated therapeutic composition
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
RU2019103297A (ru) 2016-07-11 2020-08-11 Интек Фарма Лтд. Гастроретентивные составы для перорального введения и пути их применения
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
EP3509585B1 (en) 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US10869842B1 (en) 2016-09-07 2020-12-22 David P Summers Transdermal delivery of pharmaceutical agents
US20200163931A1 (en) 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
JP2019537628A (ja) 2016-11-02 2019-12-26 ティクン オラム リミテッドＴｉｋｕｎ Ｏｌａｍ ＬＴＤ 併用療法
WO2018083697A1 (en) 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
CA3081755A1 (en) 2016-11-07 2018-05-11 Avidas Pharmaceuticals Llc Therapeutic cannabinoid topical formulations without phospholipids and permeation enhancers
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EP3551182B1 (en) 2016-12-06 2025-03-19 Topical Innovations B.V. Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
WO2018112138A1 (en) 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
US20180311181A1 (en) 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety
WO2018126225A1 (en) 2016-12-29 2018-07-05 International Bioceutical Company, Llc Modular transdermal delivery system and associated methods of manufacture and use
US20180311180A1 (en) 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US10675264B2 (en) 2017-02-07 2020-06-09 Elevate Technologies Llc Terpene-based compositions, methods of preparations and uses thereof
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CA3064782A1 (en) 2017-05-26 2018-11-29 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US10945967B2 (en) 2017-05-30 2021-03-16 Jae Wang. Song Formulations of a transdermal patch for pain management
CA3065167A1 (en) 2017-05-31 2018-12-06 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
CA3103178A1 (en) 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
CA3068383A1 (en) 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid product for women health
US20190134121A1 (en) 2017-08-08 2019-05-09 Steven Bermudez Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process
WO2019034936A2 (en) 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd TERPENE ENRICHED CANNABINOID COMPOSITION AND PROCESSING METHOD
JP2020530857A (ja) 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
US20200352901A1 (en) 2017-09-02 2020-11-12 Scientific Holdings, Llc Tetrahydrocannabinol modulators
CN109498606A (zh) 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
JOP20200045A1 (ar) 2017-09-19 2020-02-27 Zynerba Pharmaceuticals Inc كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
CN111801093A (zh) 2017-10-17 2020-10-20 雷米生物科学公司 用于包括cbd增强的组合物、制剂和嵌合体的部分的改善的递送系统
US10307392B2 (en) 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
ES3064839T3 (en) 2017-11-15 2026-04-29 Univ California Combination of cannabidiol and buprenorphine and its use for the treatment of chronic pain
WO2019130215A1 (en) 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
US10722545B2 (en) 2018-01-01 2020-07-28 Alexander Kariman Compound and method for treatment of movement disorders
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
US11759473B2 (en) 2018-02-16 2023-09-19 American Nano, LLC Topical compositions incorporating silica fibers
WO2019165387A1 (en) 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
WO2019191830A1 (en) 2018-04-04 2019-10-10 Vincenzo Maida Topical cannabinoid formulations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
WO2019198056A1 (en) 2018-04-14 2019-10-17 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CN112752556A (zh) 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
US20190328884A1 (en) 2018-04-30 2019-10-31 Chemic Laboratories, Inc. Compositions and methods of their use
WO2019224824A1 (en) 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US10864189B2 (en) 2018-06-29 2020-12-15 Jenna Borok Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care
GB201811833D0 (en) 2018-07-19 2018-09-05 Medherant Ltd Patch
GB201811834D0 (en) 2018-07-19 2018-09-05 Medherant Ltd Patch
US20200054887A1 (en) 2018-08-15 2020-02-20 Bruce H. Levin Topical Therapeutics
US10751299B2 (en) 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
CA3060926A1 (en) 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
IL261774B (en) 2018-09-13 2020-04-30 Unv Medicine Ltd Preparations for the treatment of skin problems
US11357958B2 (en) 2018-10-25 2022-06-14 Medtronic Vascular, Inc. Devices and techniques for cardiovascular intervention
WO2020115751A1 (en) 2018-12-06 2020-06-11 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of alzheimer's disease and dementia
WO2020123625A1 (en) 2018-12-11 2020-06-18 The Regents Of The University Of Michigan Co-crystals, method and apparatus for forming the same
IL325123A (en) 2018-12-14 2026-02-01 Harmony Biosciences Man Inc Treating 22q11.2 Deficiency Syndrome with Cannabidiol
AU2019412825A1 (en) 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
AU2019413789B2 (en) 2018-12-29 2025-05-29 Buzzelet Development And Technologies Ltd. Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
EP3906025A4 (en) 2019-01-04 2022-09-21 Columbia Care LLC CANNABINOID TOPICAL FORMULATIONS
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
WO2020157639A1 (en) 2019-01-29 2020-08-06 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid composition and method of treatment for treating conditions and/or symptoms associated with autism spectrum disorder
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
US20210015740A1 (en) 2019-03-04 2021-01-21 Michael Harvey Greenspan Topical cannabinoid compositions, delivery systems, and uses for pain relief
EP3934641A4 (en) 2019-03-07 2022-12-21 Ilera Therapeutics LLC FORMULATIONS FOR THE TREATMENT OF SYMPTOMS ACCOMPLISHED WITH AUTISM
WO2020183350A1 (en) 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Transdermal patch kit with transdermal dosage units
KR20220003519A (ko) 2019-03-26 2022-01-10 윈산토르, 아이엔씨. 말초 신경병증 치료를 위한 국소 제형
WO2020198883A1 (en) 2019-04-03 2020-10-08 Stratemeyer Trinczek Ely Nigel Transdermal medicament
US20200330379A1 (en) 2019-04-17 2020-10-22 Navinta NV, Inc. Non-oral cannabinoid formulation and method of treatment
WO2020220092A1 (en) 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
US20200345653A1 (en) 2019-05-02 2020-11-05 Kenda Hansen Transdermal Composition
CA3138630A1 (en) 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US20200345685A1 (en) 2019-05-02 2020-11-05 Christopher Ayo Otiko Topical application of medical cannabis
US20200352849A1 (en) 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
EP3975703A4 (en) 2019-05-28 2023-07-12 Tech Swerve LLC PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHOD OF USE
US10842758B1 (en) 2019-06-18 2020-11-24 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations containing cannabidiol
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
US20230090094A1 (en) 2019-07-02 2023-03-23 Ellevet Sciences Hemp extract for treatment of pain, cancer and epilepsy in animals
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
EP4512472A3 (en) 2019-08-05 2025-04-30 CS Medica A/S Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
WO2021050429A1 (en) 2019-09-10 2021-03-18 Pureform Global, Inc. Topical composition for treatment of pain
WO2021055499A1 (en) 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
US11951079B2 (en) 2019-10-03 2024-04-09 Kongkrit Chaiyasate Topical cannabidiol composition
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US11318093B2 (en) 2019-11-08 2022-05-03 Pac-Dent, Inc. Dental topical anesthetic gel
US20210145764A1 (en) 2019-11-15 2021-05-20 Brigham Young University Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
WO2021102353A1 (en) 2019-11-20 2021-05-27 Canole Llc Combination cannabinoid-nad+ precursor formulation for treatment of inflammation and methods related thereto
US20210244680A1 (en) 2020-02-10 2021-08-12 Ghassan S. Kassab Wearable liposomal cannabidiol transdermal patch
WO2021163238A1 (en) 2020-02-11 2021-08-19 Ghalili, Babak Cannabinoid and menthol transdermal delivery systems and methods
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021177937A1 (en) 2020-03-02 2021-09-10 Babak Ghalili Cannabinoid and menthol compositions and methods
WO2021177940A1 (en) 2020-03-03 2021-09-10 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
US20210346310A1 (en) 2020-04-20 2021-11-11 Pike Therapeutics, Inc. Transdermal and/or topical, pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
EP4210714A4 (en) 2020-05-19 2025-01-29 Mig Usa, Llc TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
WO2022003623A1 (en) 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047541A1 (en) 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating parkinson's disease
MX2023006561A (es) 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273895A1 (en) * 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
WO2019140321A1 (en) * 2018-01-12 2019-07-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery

Also Published As

Publication number Publication date
EP4045024A1 (en) 2022-08-24
JP2022551730A (ja) 2022-12-13
MX2022004258A (es) 2022-05-26
US12097293B2 (en) 2024-09-24
CA3155181A1 (en) 2021-04-22
EP4045024A4 (en) 2023-10-25
US20210106540A1 (en) 2021-04-15
WO2021074790A1 (en) 2021-04-22
AU2020366147A1 (en) 2022-04-07
CN114555068A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
US12097293B2 (en) Transdermal delivery of cannabidiol
US12121617B2 (en) Transdermal delivery of cannabidiol
AU2020361741B2 (en) Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
EP4110325A1 (en) Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
US20220047525A1 (en) Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
US12409131B2 (en) Transdermal delivery of dronabinol
AU2020358869A1 (en) Transdermal delivery of dronabinol
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
CA3213953A1 (en) Pharmaceutical composition and method for treating seizure disorders
WO2022224184A1 (en) Transdermal pharmaceutical formulations for the treatment of chronic pain
US12268699B2 (en) Transdermal delivery of tetrahydrocannabinol
WO2022219468A1 (en) Transdermal delivery of cannabidiol
WO2026018119A1 (en) Transdermal delivery of tetrahydrocannabinol
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PIKE THERAPEUTICS INC.

Free format text: FORMER NAME(S): PIKE THERAPEUTICS INC., 1219014 B.C. LTD.

FGA Letters patent sealed or granted (standard patent)